Neoplasms

All Conditions

Skin and Connective Tissue Diseases

Urinary Tract, Sexual Organs, and Pregnancy Conditions

Blood and Lymph Conditions

Immune System Diseases

Heart and Blood Diseases

Digestive System Diseases

Rare Diseases

Carcinoma

Melanoma

Carcinoma, Renal Cell

Lymphoma

Multiple Myeloma

Neoplasms, Plasma Cell

Liver Neoplasms

Neoplasms by Histologic Type

Hemostatic Disorders

Blood Coagulation Disorders

Vascular Diseases

Paraproteinemias

Blood Protein Disorders

Hematologic Diseases

Hemorrhagic Disorders

Lymphoproliferative Disorders

Immunoproliferative Disorders

Adenocarcinoma

Neoplasms, Glandular and Epithelial

Kidney Neoplasms

Urologic Neoplasms

Urogenital Neoplasms

Urogenital Diseases

Female Urogenital Diseases

Pregnancy Complications

Female Urogenital Diseases and Pregnancy Complications

Kidney Diseases

Urologic Diseases

Male Urogenital Diseases

Renal Cell Carcinoma

Lymphosarcoma

Primary Liver Cancer

Clear Cell Renal Cell Carcinoma

MRX34

O'Neill VIncent, MD

This is a study to evaluate the safety of MRX34 in patients with primary liver cancer or other selected solid tumors or hematologic malignancies. The drug is given intravenously, for 5 days in a row and then two weeks off.

This is a Phase I, open-label, multicenter, dose-escalation study to investigate the safety, Pharmacokinetics and Pharmacodynamics of the micro ribonucleic acid (microRNA) MRX34, in patients with unresectable primary liver cancer or advanced or metastatic cancer with or without liver involvement or hematologic malignancies. MRX34 will be administered daily x 5 with 2 weeks off (total of 21 days) for 3 cycles followed by a no-treatment observation period.

A Multicenter Phase I Study of MRX34, MicroRNA miR-RX34 Liposomal Injection

Dose-limiting toxicity (DLT) in 3-6 patients at the end of one treatment cycle

Cancer Prevention Research Institute of Texas

Mirna Therapeutics, Inc.

Neuroendocrine Tumors

Neuroectodermal Tumors

Neuroectodermal Tumors, Primitive

Neoplasms, Germ Cell and Embryonal

Neoplasms, Nerve Tissue

Nevus, Pigmented

Nevus

Nevi and Melanomas

Skin Neoplasms

Skin Diseases

Neuroendocrine Tumor

Neuroepithelioma

Anti-Inflammatory Agents

Antineoplastic Agents

Antiemetics

Gastrointestinal Agents

All Drugs and Chemicals

Dexamethasone

Dexamethasone acetate

BB 1101

Glucocorticoids

Hormones

Hormone Antagonists

Antineoplastic Agents, Hormonal

Liposomal Injection of MRX34 for 5 days followed by 16 days rest with premedication of dexamethasone daily.

Treatment of melanoma with pharmacodynamics biopsy of tissue and blood

Premedication during the week of treatment

Susan Smith, MSN

This study is designed to investigate the biomarkers, pharmacodynamics and pharmacokinetics of the liposomal micro-ribonucleic acid-34 (microRNA-34, miR-34). Melanoma patients with easily accessible lesions will undergo serial biopsies and serial blood samples will be collected.

MRX34 Induction Therapy consists of 3 cycles of MRX34 treatment given over an approximately 8 week period. Dexamethasone 10 mg PO (or IV) will be given as premedication. On Days 1-5 of each treatment cycle, MRX34 will be given as a daily infusion followed by 16 days of rest. At screening a tumor biopsy sample will be required from all patients. Additional biopsies will be collected at Cycle 1 Day 3 and the end of Cycles 1 and 3 (Day 18 +/- 1 day)

Pharmacodynamics Study of MRX34, MicroRNA Liposomal Injection in Melanoma Patients With Biopsy Accessible Lesions

A Multicenter Phase 1B Pharmacodynamics Study of MRX34, MicroRNA miR-Rx34 Liposomal Injection, in Patients With Advanced Melanoma and Biopsy Accessible Lesions

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
A Multicenter Phase I Study of MRX34, MicroRNA miR-RX34 Liposomal Injection	NCT01829971	Primary Liver C... SCLC Lymphoma Melanoma Multiple Myelom... Renal Cell Carc... NSCLC	MRX34	18 Years -	Mirna Therapeutics, Inc.
Pharmacodynamics Study of MRX34, MicroRNA Liposomal Injection in Melanoma Patients With Biopsy Accessible Lesions	NCT02862145	Melanoma	MRX34 Dexamethasone	18 Years - 95 Years	Mirna Therapeutics, Inc.
A Multicenter Phase I Study of MRX34, MicroRNA miR-RX34 Liposomal Injection	NCT01829971	Primary Liver C... SCLC Lymphoma Melanoma Multiple Myelom... Renal Cell Carc... NSCLC	MRX34	18 Years -	Mirna Therapeutics, Inc.

Spots Global Cancer Trial Database for mrx34

Every month we try and update this database with for mrx34 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for mrx34

Every month we try and update this database with for mrx34 cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for mrx34 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.